Oslo Science Hub will provide an inviting and inclusive area for everyone on the Radium Hospital Campus and contribute to faster development of new cancer treatments. Illustration: Nordic Office of Architecture

New plans for the Radium Hospital Campus

/in , /by

Article edit: On Tuesday 20 August 2024, an agreement was signed between Oslo City Council and Oslo Science Hub to sell the lots necessary for the building.

The planned buildings will transform the Oslo Montebello area into an international power centre for cancer research.

The drawings for Oslo Science Hub, the next expansion phase of Oslo Cancer Cluster Innovation Park, have been sent to Oslo City for approval and were recently presented at a meeting during Arendalsuka.

“Our vision is to create a vital and inclusive environment where researchers, entrepreneurs and companies at the Radium Hospital Campus can meet and collaborate to contribute to developing better cancer treatments,” stated Thomas London, CEO of Oslo Science Hub.

Thomas London, CEO of Oslo Science Hub, wants to contribute to developing new cancer treatments and offer a better environment for cancer patients and next of kin at the Radium Hospital. Photo: Sofia Linden

The new building will be 40 000 square metres, accommodate up to 2 000 employees, and offer state-of-the-art laboratories, complementary hospital services, biobank facilities and offices. There will be a mixture of tenants from the public and private sectors in health, oncology and biotechnology. The vision includes creating a “miniature village” with town squares, cafés, restaurants and shops to facilitate interactions between employees, patients and visitors.

A European power centre

“The Radium Hospital Campus is a European power centre for research, clinical treatment and innovation. We have a burning desire to develop the campus into a good place to do pharmaceutical research and development, to attract international key players, which are currently the missing link in the area,” commented Jónas Einarsson, founder of Oslo Cancer Cluster and CEO of Radforsk investment fund.

Oslo Science Hub will be built next to Oslo Cancer Cluster Innovation Park, the Institute for Cancer Research and Oslo University Hospital. Illustration: Nordic Office of Architecture

The Radium Hospital Campus already includes Oslo University Hospital, a Comprehensive Cancer Centre focused on innovation with its newly built clinic and proton centres. The area also encompasses the Institute for Cancer Research, which boasts solid research groups performing world-class research in several oncology areas.

Right next door is Oslo Cancer Cluster Innovation Park housing a mixture of public and private stakeholders, such as the Cancer Registry of Norway, Oslo University Hospital, and the Oslo Cancer Cluster Incubator with different start-ups and established companies.

A fourth building block is currently under construction, which will accommodate a restaurant, a cafeteria, a training centre, the non-profit organisations Active Against Cancer and Youth Cancer, and the international life science company Thermo Fisher Scientific.

Lack of space

“The area needs this type of building. We have been there for 30 years and are missing areas for expansion, special laboratories, and cafés and restaurants,” commented Geir Hetland, Chief Financial Officer of Thermo Fisher Scientific.

Thermo Fisher Scientific Norway was based on the Norwegian invention “Ugelstad-kulene” (later known as Dynabeads). The technology was developed in close collaboration with the Radium Hospital and today it is used in 5 billion diagnostic tests every year. Thermo Fisher Scientific need space to continue the company’s research and development in Norway.

Oslo Science Hub will bring laboratories, office spaces, biobank facilities and more, which will contribute to attracting international key players in research and development. Illustration: Nordic Office of Architecture

“We have spent an unnecessary amount of time through the years handling the lack of space for our companies. We have needs from start-ups, established companies and the hospital. I am happy we have built this ecosystem with all its positive dynamics and see that it is essential for start-ups to collaborate with international companies. So there needs to be further investments both on a national and local level for the health industry to succeed,” commented Ketil Widerberg, general manager of Oslo Cancer Cluster.

More than a hospital

For the patients, next of kin and health workers, these facilities are also sorely needed, since there are currently few places to meet, exercise, enjoy food or venture outdoors.

Sigbjørn Smeland, director of the Norwegian Radium Hospital, commented:

“My predecessor Jan Vincent Johannessen coined the term ‘more than a hospital’. This is clearly an extension of his work and shows that building culture and creating value over time releases good forces. We will offer the patient more than treatment for their cancer disease. This building is incredibly valuable in the totality we offer as a Comprehensive Cancer Centre.”

The new building will offer open and airy spaces for employees, visitors, patients and next of kin to meet and interact. Illustration: Nordic Office of Architecture

Ingrid Stenstadvold Ross, general secretary of the Norwegian Cancer Society, added:

“The most important thing is that the Radium Hospital is a spearhead in cancer care, that patients can get the best treatments available. The health services are also under pressure, meaning it is more important than ever to attract and keep skillful health workers. These facilities will help to do both these things.”

From words to action

Leader of the Oslo City Council Eirik Lae Solberg (The Conservative Party of Norway) made the campaign promise last year to ensure the sale of the real estate needed to build Oslo Science Hub.

“This is not a regular real estate issue. We need to prioritise this. We have a milieu that contributes to saving lives. From Oslo’s point of view, it is fantastic to have this industry. We have to support it if we want to be competitive in the future as a capital city,” Lae Solberg said.

Solveig Vitanza (the Labour Party of Norway), parliamentary representative, and Eirik Lae Solberg (the Conservative Party of Norway), leader of the Oslo City Council, promised their support to the development of the Radium Hospital Campus. Photo: Sofia Linden

Secretary General of the Ministry of Health and Care Services Cathrine Lofthus was also excited to see the plans taking concrete shape:

“I believe we need physical meeting places. We are not good enough at collaborating with the industry, but we hope to be better. This is exactly what we are talking about when we refer to the Roadmap for the Health Industry and Health as an Export Priority.”

Parliamentary representative Solveig Vitanza (Labour Party of Norway) expressed her ambition to go from words to action:

“We must facilitate the whole value chain: testing and piloting, clinical studies, clusters, health technology and data. We are in a very special time, with a recent pandemic and a geopolitical situation, which makes health a higher priority than ever.”

Watch the meeting here (in Norwegian):

Oslo Science Hub facts

  • Planned to be finished: 2030
  • Brutto area: 40 000 sqm
  • Potentially 2000 employees
  • State-of-the-art laboratories, complementary hospital services, biobank and offices
  • Mix of tenants similar to Oslo Cancer Cluster Innovation Park: public and private actors in oncology and biotechnology, especially international pharmaceutical industry
  • Open areas for the public, such as shops, restaurants, cafes and roof terraces

The Radium Hospital Campus facts

  • One of Europe’s largest campuses for cancer research and treatment
  • Consists of the new Radium Hospital, which opens in September 2024, the Institute for Cancer Research and Oslo Cancer Cluster Innovation Park and Incubator (OCCI)
  • Total building mass is 105 000 sqm
  • About 3 500 people work on the campus in different enterprises, while Ullern Upper Secondary School, which is an integrated part of OCCI, has 970 students
  • OCCI expands with 12 000 sqm that will be finished in 2025, which will include Thermo Fisher Scientific with several research departments, Active Against Cancer and some of the companies from OCC Incubator
  • A mix of public and private institutions that collaborate across organisations
  • Ullern Upper Secondary School have a school collaboration with other enterprises on campus, which includes placements and mentorships
  • Oslo Cancer Cluster Incubator with 16 start-up companies
  • A part of Oslo Science City, which is Norway’s first innovation district and an important part of Oslo City’s investment as a business capital

The post New plans for the Radium Hospital Campus first appeared on Oslo Cancer Cluster.

Oslo Cancer Cluster Innovation Park: A powerhouse for the development of cancer treatments

/in , , , , , , /by

Innovation Park and the surrounding buildings

This article was originally published in Norwegian on Altomdinhelse.no by Mediaplanet, and was written by Jónas Einarsson, CEO of Radforsk and initiator of Oslo Cancer Cluster, Oslo Cancer Cluster Incubator and Oslo Cancer Cluster Innovation Park. 

We wish to expand Oslo Cancer Cluster Innovation Park with close to 50 000 square metres the next five to seven years. The goal is to develop even better cancer treatments to improve the lives of cancer patients, in close collaboration with the ecosystem around the park.

On 24 August 2015, the Norwegian Prime Minister Erna Solberg opened Oslo Cancer Cluster Innovation Park. In her speech, she said: “Oslo Cancer Cluster Innovation Park will fulfil an important role in the development of the cancer treatments of the future.”

That moment was the starting point for a unique collaboration between cancer researchers, clinicians, teachers, students, business developers and numerous other professions that are needed to develop tomorrow’s cancer treatments.

All of us that work here share a common vision: Oslo Cancer Cluster Innovation Park and the environment around the Norwegian Radium Hospital and the Institute for Cancer Research (Oslo University Hospital) should be an international powerhouse for the development of cancer treatments.

The beginning of a success story

Five years after the opening, we are still fulfilling that vision every day. I would even go so far as to say that we have contributed to a success story:

  • Oslo Cancer Cluster Incubator houses nine start-up companies today, and we are working closely with seven other companies that are located other places due to limited space.
  • The 24 private and public tenants of Oslo Cancer Cluster Innovation Park want more space, since their operations are ever growing.
  • Ullern Upper Secondary School is one of the most sought-after schools in Oslo and the number of students is ever increasing. The students are offered the opportunity to participate in the school collaboration with Oslo Cancer Cluster, to educate the researchers and entrepreneurs of tomorrow. In the autumn of 2019, the researcher programme was initiated at Ullern, which is a unique opportunity for students in Oslo to specialise in biomedical subjects.

Many developments planned

Everything mentioned above is only what is happening inside the Innovation Park. In the nearby area, there are many unique developments that will change the treatment of cancer patients in coming years:

  • In 2023, the new clinic building of the Norwegian Radium Hospital and its specialised proton centre will open.
  • The Institute for Cancer Research is being developed further under the proficient management of Professor Kjetil Taskén. The talented researchers at the Institute are delivering internationally renowned research every day.
  • Oslo University Hospital is the only hospital in Scandinavia accredited as a “Comprehensive Cancer Center”. The accreditation demands constant development of research, infrastructure and treatments.

Still a way to go

Things are still far from perfect. Almost everyday in the news, there are discussions about whether Norwegian cancer patients are offered the best cancer treatments. I believe we still have a way to go. In order to give better cancer treatments, we must heavily invest in the development of:

  • Molecular diagnostics
  • Cell and gene therapy
  • Precision medicine
  • The treatment of antibiotic resistance

Because of the success we have had so far with the Oslo Cancer Cluster Innovation Park and the need to strengthen cancer care further, we wish to expand the Oslo Cancer Cluster Innovation Park during the next five to seven years with close to 50 000 square metres. The first expansion will total 7 000 square metres. The planning scheme begins this year and the building itself will be located between the Innovation Park and the Institute for Cancer Research.

Enormous ambitions

The expansion of the Innovation Park is an important supplement to the plans on developing Oslo into Oslo Science City. We are also a living example of how public-private partnerships is the way to go in order to build a sustainable health industry, like the White Paper on the Health Industry has stated.

Norwegian cancer research is world class. The 15 companies in the Radforsk portfolio has spun out of this research. We have enormous ambitions to contribute even more to the development of the cancer treatments of tomorrow – to improve the lives of cancer patients all over the world.

As Prime Minister Erna Solberg said in her speech on 24 August 2015: “Smart minds and new ideas, students and professors, Norwegians and foreigners, founders and employees. Together for a common goal: to improve the treatment of the approximately 30 000 Norwegians that are diagnosed with cancer every year.”

That statement is still true today.

 

Oslo Cancer Cluster Innovasjonspark:
Kraftsenter for utvikling av kreftbehandling

Vi ønsker å utvide Oslo Cancer Cluster Innovasjonspark med nærmere 50.000 km² de neste fem til syv årene. Målet er å utvikle enda bedre kreftbehandling til det beste for kreftpasienter, i tett samarbeid med økosystemet rundt parken.

Av Jónas Einarsson, administrerende direktør i Radforsk og initiativtaker til Oslo Cancer Cluster, Oslo Cancer Cluster Inkubator og Oslo Cancer Cluster Innovasjonspark.

Den 24. august 2015 åpnet Statsminister Erna Solberg Oslo Cancer Cluster Innovasjonspark. I sin tale sa hun: «Oslo Cancer Cluster Innovasjonspark vil fylle en viktig rolle i utforming av fremtidens kreftbehandling.»

Og med det gikk startskuddet gikk for et unikt samarbeid mellom kreftforskere, klinikere, lærere, elever, forretningsutviklere og en rekke andre profesjoner som trengs for å utvikle morgendagens kreftbehandling.

Felles for alle oss som jobber her, er at vi har én visjon: Oslo Cancer Cluster Innovasjonspark og miljøet rundt med Radiumhospitalet og Institutt for Kreftforskning, skal være et internasjonalt kraftsenter for utvikling av kreftbehandling.

Fem år etter åpningen så lever vi ut denne visjonen hver dag. Jeg vil tørre å påstå at det vi har bidratt til er en suksess:

  • Oslo Cancer Cluster Incubator huser i dag ni oppstartsbedrifter, og vi jobber tett med syv andre som sitter andre steder og som det ikke er plass til
  • Oslo Cancer Cluster Innovasjonspark sine 24 private og offentlige leietakere ønsker mer plass da de stadig utvider sin virksomhet
  • Ullern videregående skole er en av de best søkte skolene i Oslo, og øker stadig elevtallet. Elevene på skolen får tilbud om å delta i det skolefaglige samarbeidet med Oslo Cancer Cluster, for å utdanne morgendagens forskere og entreprenører. Høsten 2019 startet Forskerlinja, et unikt tilbud til skoleelever i Oslo om fordypning i biomedisinske fag

Dette er bare inne i Innovasjonsparken. I området rundt oss skjer det unike ting som endrer måten pasienter med kreft blir behandlet på om få år:

  • I 2023 åpner det nye klinikkbygget på Radiumhospitalet med et spesialisert protonsenter
  • Institutt for Kreftforskning blir stadig videreutviklet under kyndig ledelse av professor Kjetil Taskén. De dyktige forskerne ved instituttet leverer daglig internasjonalt, anerkjent forskning
  • Oslo universitetssykehus er som eneste sykehus i Skandinavia akkreditert som et «Komplett kreftsenter», «Comprehensive Cancer Center». Akkrediteringen krever konstant utvikling av forskning, infrastruktur og behandling

Likevel er ikke tingenes tilstand rosenrød. I media kan vi nesten daglig lese diskusjoner om hvorvidt kreftbehandlingen pasienter i Norge tilbys er den beste. Min påstand er at vi har mye å gå på. For å gi bedre kreftbehandling må vi satse tungt på å utvikle:

  • Molekylær diagnostikk
  • Celle- og genterapi
  • Presisjonsmedisin
  • Behandling av antibiotikaresistens

På bakgrunn av den suksessen vi har hatt med Oslo Cancer Cluster Innovasjonspark så langt, og behovet for å styrke kreftomsorgen ytterligere, ønsker vi de neste fem til syv årene å utvide Oslo Innovasjonsparken med nær 50.000 km². Den første utvidelsen vil være på 7000 km². Prosjekteringen starter i år, og selve bygget vil ligge mellom Innovasjonsparken og Institutt for Kreftforskning.

Utvidelsen av Innovasjonsparken er et viktig tilskudd til planene om å utvikle Oslo som en kunnskapshovedstad, Oslo Science City. Vi er i tillegg et levende eksempel på at privat-offentlig samarbeid er veien å gå for å bygge en bærekraftig helsenæring, slik Stortingsmeldingen om helsenæring slår fast.

Norsk kreftforskning er i verdensklasse. Våre 15 bedrifter i Radforsk-porteføljen er spunnet ut av denne forskningen. Vi har enorme ambisjoner om at vi kan bidra enda mer til utviklingen av morgendagens kreftbehandling – til det beste for kreftpasienter over hele verden.

Som Statsminister Erna Solberg sa i sin tale den 24. august 2015: «Kloke hoder og nye ideer, studenter og professorer, nordmenn og utlendinger, gründere og ansatte. Samlet med ett felles mål: å bedre behandlingen til de om lag 30.000 nordmenn som blir diagnostisert med kreft hvert år.»

Det er like sant i dag.

Oslo Cancer Cluster Innovasjonspark med Institutt for Kreftforskning, Oslo Universitetsykehus, til venstre. Foto: Christian Tandberg/Oslo Cancer Cluster

Oslo Cancer Cluster Innovasjonspark med ny eierstruktur

/in , , /by

Oslo Cancer Cluster Innovasjonspark

Please scroll down for a version of this article in English.

Dette er endringene i eierstrukturen for Oslo Cancer Cluster (OCC) Innovasjonspark og OCCI Holding AS i begynnelsen av 2020.

OCC Innovasjonspark har siden starten vært eid av Utstillingsplassen Eiendom AS (UPL), Industrifinans OCCI AS, Siva Eiendom, Oslo Cancer Cluster, Radiumhospitalets Legat for Kreftforskning og OBOS Eiendom.

OBOS solgte sin eierandel til øvrige eiere tidligere i 2019. I en ny transaksjon 13. januar 2020 solgte UPL og Industrifinans OCCI AS sine aksjer til en ny eier, OCCI Invest AS. I samme transaksjon har Oslo Cancer Cluster solgt en mindre prosentandel.

Et kraftsenter innen kreft

OCC Innovasjonspark ligger på Montebello i Oslo ved siden av Oslo Universitetssykehus Radiumhospitalet og Institutt for kreftforskning. Parken åpnet offisielt i august 2015.

Innovasjonsparken huser mange bedrifter som utvikler kreftbehandlinger og diagnostikk, deler av Oslo Universitetssykehus, Kreftregisteret, Radforsk, Oslo Cancer Cluster Incubator, Oslo Cancer Cluster og Ullern videregående skole.

UPL og Industrifinans OCCI AS har sammen med de øvrige eierne, gjennom sitt eierskap i OCCI Holding AS, vært med på å utvikle OCC Innovasjonspark til et kraftsenter innen kreft. UPL har også hatt prosjektansvar og ansvar for å forvalte eiendommen.

– Vi er svært takknemlig for de investorene som investerte i et risikoprosjekt, som var nytt og banebrytende før det åpnet, sier Jónas Einarsson, styremedlem i OCC Innovasjonspark og Oslo Cancer Cluster.

Innovasjonsparken er i dag utleid til viktige samfunnsfunksjoner, og har blitt en naturlig del av et viktig økosystem for kreftforskning i Norge.

Gir stafettpinnen videre

Som en del av sin strategi, gir tidligere eiere nå stafettpinnen videre til nye og langsiktige eiere i OCCI Invest AS. Selskapet er eid av solide eiere, og det er etablert og forvaltet av Pareto Securities AS.

– Konseptet til innovasjonsparken utvikler vi videre – med nye langsiktige investorer. De kan vente seg mye av framtidig utvikling her, og jeg ser fram til å utvikle prosjektet videre med nye og gamle eiere, sier Einarsson.

Tron Sanderud, administrerende direktør i UPL, er også stolt av prosjektet. UPL vil fortsette som forvalter av eiendommen inntil videre.

Nytt bygg planlagt

Innovasjonsparken består i dag av ca. 36 000 kvm kontorer, laboratorier, møterom, auditorier, undersøkelsesrom og videregående skole for over 900 elever.

– Vi har planlagt å bygge nye 7 000-8 000 kvm i andre byggetrinn. Dette bygget vil bli utviklet med nye og spennende prosjekter i samarbeid mellom akademiske institusjoner og industrien. Vi planlegger å starte prosjekteringen av det nye bygget i løpet av 2020, forteller Einarsson.

Nye eierandeler i januar 2020

OCCI Invest AS: 53.7 %
SIVA Eiendom Holding AS: 40,7 %
Radiumhospitalets legat for kreftforskning: 4.6 %
Oslo Cancer Cluster: 1,0 %

 

Oslo Cancer Cluster Innovation Park gains new owners

The following changes are being made to the ownership of Oslo Cancer Cluster (OCC) Innovation Park and OCCI Holding AS as of the beginning of 2020.

OCC Innovation Park has since its opening been owned by Utstillingsplassen Eiendom AS (UPL), Industrifinans OCCI AS, Siva Eiendom, Oslo Cancer Cluster, Radiumhospitalets Legat for Kreftforskning and OBOS Eiendom.

OBOS sold their shares to the other owners earlier in 2019. In another transaction on 13 January 2020, UPL and Industrifinans OCCI AS sold their shares to a new owner, OCCI Invest AS. In the same transaction, Oslo Cancer Cluster has sold a smaller percentage of their shares.

A power centre in cancer

OCC Innovationpark is located in the Montebello area of Oslo, next to the Oslo University Hospital (Radiumhospitalet) and the Institute for Cancer Research. The park was officially opened in August 2015.

The Innovation Park houses many companies that develop cancer treatments and diagnostics, parts of Oslo University Hospital, the Cancer Registry of Norway, Radforsk, Oslo Cancer Cluster Incubator, Oslo Cancer Cluster and Ullern Upper Secondary School.

UPL and Industrifinans OCCI AS have together with the other owners, through their ownership in OCCI Holding AS, developed OCC Innovation Park to a power centre in cancer. UPL have also been responsible for projects and for managing the property.

“We are very thankful to the investors that invested in this risk project, which was new and ground-breaking before it opened,” said Jónas Einarsson, board member in OCC Innovation Park and Oslo Cancer Cluster.

The Innovation Park is today leased for important services to society and has become a natural part of an important ecosystem for cancer research in Norway.

Passing on the baton

As a part of their strategy, the former owners are now passing on the baton to new and long-term owners in OCCI Invest AS. The company is owned by solid owners and is established and managed by Pareto Securities.

“We are continuing to develop the concept of the Innovation Park – with new, long-term investors. They can expect a lot of future developments here and I look forward to develop this project further with new and current owners,” Einarsson said.

Tron Sanderud, CEO of UPL, is also proud of the project. UPL will continue as manager of the property.

New building planned

The Innovation Park today consists of approximately 36 000 square meters of offices, laboratories, meeting rooms, auditoriums, patient screening rooms and an upper secondary school with over 900 students.

“We have planned to build 7 000-8 000 square metres as part of the second construction phase. This new building will be developed with new and exciting projects in collaboration with academic institutions and the industry. We are planning to start the scheme for the new building during the course of 2020,” said Einarsson.

New shareholding as of January 2020

OCCI Invest AS: 53.7 %
SIVA Eiendom Holding AS: 40,7 %
Radiumhospitalets legat for kreftforskning: 4.6 %
Oslo Cancer Cluster: 1,0 %

 

Sign up to our monthly newsletter

Thermo Fisher Scientific Norway was one of many stops during the guided tours through Oslo Cancer Cluster Innovation Park for students of Ullern Upper Secondary School.

A peak into the cancer research world

/in , , , /by

ThermoFisher Scientific Norway lectures students at Ullern

Ullern Upper Secondary School is unique, because it shares its building with world-class cancer researchers. Last month, all new Ullern students got to experience this first-hand.

This year’s School Collaboration Days in Oslo Cancer Cluster Innovation Park were held right before the autumn holiday. All the first-year classes at Ullern Upper Secondary School were given a guided tour around the Innovation Park to get to know the companies that they share their everyday lives with.

The purpose of the School Collaboration Days is to give the first-year students at Ullern Upper Secondary School an understanding of what the different companies in the Innovation Park and departments of Oslo University Hospital do.

The common denominator for all of them is cancer and many are developing new cancer treatments. While the Cancer Registry of Norway are collecting statistics and doing cancer research, Sykehusapotekene (Southern and Eastern Norway Pharmaceutical Trust) produce chemotherapy and antibodies for patients that are admitted to The Norwegian Radium Hospital and the Department of Pathology (Oslo University Hospital) gives the cancer patients their diagnoses.

 

IN PICTURES

The student guided tours of Oslo Cancer Cluster Innovation Park

Jonas Einarsson lecturing to students at Ullern

True to tradition, Jónas Einarsson, CEO of the evergreen fund Radforsk, opened the School Collaboration Days in Kaare Norum auditorium with a common lecture. In this image, Einarsson is talking about the development of the Montebello area, which Oslo Cancer Cluster Innovation Park is a part of. The first Radium Hospital was opened in 1932 and the following year Ullern School was moved from Bestum to the same place that houses Oslo Cancer Cluster Innovation Park today.

 

Kreftregisteret lecturing to students at Ullern.

Elisabeth Jakobsen, Head of Communications of the Cancer Registry of Norway, tells the first year students about what they do and the risk factors for developing cancer. Also, she asked the students several questions about how to regulate the sales of tobacco, e-cigarettes and many other things.

 

Thor Audun Saga is the CEO of Syklotronsenteret (“the Norwegian medical cyclotron centre”). He told the students about what they do, what a cyclotron is and how they use cyclotrons to develop cancer diagnostics.

 

ThermoFisher Scientific Norway lectures students at Ullern

The management of Thermo Fisher Scientific Norway are also housed in the Oslo Cancer Cluster Innovation Park. They told the students about the Norwegian invention called “Ugelstadkulene”. This is both the starting point for million of diagnostic tests across the world and revolutionary (CAR T) cancer treatments, 45 years after they were invented.

 

Students guided through the Oslo Cancer Cluster Incubator Laboratory

The tour was ended with a walk through the laboratory of the Oslo Cancer Cluster Incubator. The students were given an inside look at the work done and instruments used by the cancer researchers in the lab. This area is only one or two floors above their regular class rooms. The student could see first-hand the opportunities there are in pursuing a career in research, entrepreneurship and innovation.